Ross N. England, Ph.D.
Affiliations: | 2015 | Physiology | Temple University, Philadelphia, PA, United States |
Area:
Physiology Biology, Pathology, Molecular BiologyGoogle:
"Ross England"Parents
Sign in to add mentor| Michael V. Autieri | grad student | 2015 | Temple University | |
| (Cellular mechanisms of the anti-inflammatory effects of interleukin-19.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Gabunia K, Herman A, Ray M, et al. (2017) Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL uptake in VSMC. Journal of Molecular and Cellular Cardiology |
| Kako F, Gabunia K, Ray M, et al. (2016) Interleukin-19 Induces Angiogenesis in the Absence of Hypoxia by Direct and Indirect Immune Mechanisms. American Journal of Physiology. Cell Physiology. ajpcell.00006.2016 |
| Ellison S, Gabunia K, Richards JM, et al. (2014) IL-19 reduces ligation-mediated neointimal hyperplasia by reducing vascular smooth muscle cell activation. The American Journal of Pathology. 184: 2134-43 |
| Ellison S, Gabunia K, Kelemen SE, et al. (2013) Attenuation of experimental atherosclerosis by interleukin-19. Arteriosclerosis, Thrombosis, and Vascular Biology. 33: 2316-24 |
| England RN, Preston KJ, Scalia R, et al. (2013) Interleukin-19 decreases leukocyte-endothelial cell interactions by reduction in endothelial cell adhesion molecule mRNA stability. American Journal of Physiology. Cell Physiology. 305: C255-65 |
| England RN, Autieri MV. (2012) Anti-inflammatory effects of interleukin-19 in vascular disease. International Journal of Inflammation. 2012: 253583 |
| Sommerville LJ, Kelemen SE, Ellison SP, et al. (2012) Increased atherosclerosis and vascular smooth muscle cell activation in AIF-1 transgenic mice fed a high-fat diet. Atherosclerosis. 220: 45-52 |
| Gabunia K, Jain S, England RN, et al. (2011) Anti-inflammatory cytokine interleukin-19 inhibits smooth muscle cell migration and activation of cytoskeletal regulators of VSMC motility. American Journal of Physiology. Cell Physiology. 300: C896-906 |